Arecor Therapeutics (AREC) Competitors

GBX 92.50

0.00 (0.00%)

(As of 07/26/2024 ET)

Stock Analysis Chart Competitors Headlines

AREC vs. VSN, FUM, FARN, MPH, ORPH, POLB, REDX, ETX, TRX, and SAR

Should you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Verseon (VSN), Futura Medical (FUM), Faron Pharmaceuticals Oy (FARN), Mereo BioPharma Group plc (MPH.L) (MPH), Open Orphan (ORPH), Poolbeg Pharma (POLB), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), and Sareum (SAR). These companies are all part of the "biotechnology" industry.

Arecor Therapeutics vs.

Verseon (LON:VSN) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings.

: Verseon has a net margin of 0.00% compared to Verseon's net margin of -187.05%. Arecor Therapeutics' return on equity of 0.00% beat Verseon's return on equity.
Company Net Margins Return on Equity Return on Assets
Verseon N/A N/A N/A
Arecor Therapeutics -187.05% -63.41% -30.88%
: In the previous week, Arecor Therapeutics' average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.
Company Overall Sentiment
Verseon Neutral
Arecor Therapeutics Neutral
: Verseon has higher earnings, but lower revenue than Arecor Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Verseon N/A N/A N/A -£14.30 -5.17
Arecor Therapeutics £4.57M 6.20 -£8.55M N/A N/A
: Verseon received 108 more outperform votes than Arecor Therapeutics when rated by MarketBeat users.
Company Underperform Outperform
Verseon Outperform Votes
108
64.29%
Underperform Votes
60
35.71%
Arecor Therapeutics N/A N/A
: 54.2% of Arecor Therapeutics shares are held by institutional investors. 31.3% of Arecor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verseon
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Arecor Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A

Company	Net Margins	Return on Equity	Return on Assets
Verseon	N/A	N/A	N/A
Arecor Therapeutics	-187.05%	-63.41%	-30.88%

Company	Overall Sentiment
Verseon	Neutral
Arecor Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verseon	N/A	N/A	N/A	-£14.30	-5.17
Arecor Therapeutics	£4.57M	6.20	-£8.55M	N/A	N/A

Company	Underperform	Outperform
Verseon	Outperform Votes 108 64.29%	Underperform Votes 60 35.71%
Arecor Therapeutics	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verseon	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Arecor Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Summary

Verseon beats Arecor Therapeutics on 5 of the 8 factors compared between the two stocks.

Ad American Hartford Gold Group

Dave Ramsey Makes Big Mistake Live On Air

Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.

GET THE FREE GUIDE

Get Arecor Therapeutics News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AREC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AREC vs. The Competition

Export to Excel

Metric	Arecor Therapeutics	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£28.33M	£165.26M	£5.27B	£1.48B
Dividend Yield	N/A	3.43%	2.78%	12.09%
P/E Ratio	-506.65	235.61	164.48	1,773.52
Price / Sales	6.20	16,248.84	2,079.25	296,818.97
Price / Cash	5.07	11.69	35.46	33.54
Price / Book	2.98	6.45	4.94	2.77
Net Income	-£8.55M	-£18.73M	£111.50M	£169.86M
7 Day Performance	0.76%	1.58%	2.73%	0.08%
1 Month Performance	-26.00%	5.67%	11.37%	1.47%
1 Year Performance	-51.95%	9.95%	9.92%	88.37%

Arecor Therapeutics Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VSN Verseon	0 of 5 stars 0.00 / 5 stars	N/A	N/A	+0.0%	£112.24M	N/A	-5.17	N/A	Gap Up
FUM Futura Medical	0 of 5 stars 0.00 / 5 stars	GBX 34.65 -0.1%	N/A	-39.9%	£104.45M	£3.10M	-1,732.50	12	News Coverage
FARN Faron Pharmaceuticals Oy	0 of 5 stars 0.00 / 5 stars	GBX 133 +3.5%	N/A	-44.3%	£95.77M	£-725,000.00	-324.39	34	News Coverage
MPH Mereo BioPharma Group plc (MPH.L)	0 of 5 stars 0.00 / 5 stars	N/A	N/A	+0.0%	£89.76M	N/A	-0.21	50	News Coverage Gap Down
ORPH Open Orphan	0 of 5 stars 0.00 / 5 stars	N/A	N/A	+0.0%	£67.09M	£34.71M	-25.30	179	News Coverage
POLB Poolbeg Pharma	0 of 5 stars 0.00 / 5 stars	GBX 12.90 -1.9%	N/A	+67.4%	£64.50M	N/A	-1,290.00	12	News Coverage
REDX Redx Pharma	0 of 5 stars 0.00 / 5 stars	N/A	N/A	-38.8%	£58.35M	£4.20M	-150.00	101	Gap Up High Trading Volume
ETX e-therapeutics	0 of 5 stars 0.00 / 5 stars	N/A	N/A	-50.1%	£52.59M	£295,000.00	-450.00	34	News Coverage High Trading Volume
TRX Tissue Regenix Group	0 of 5 stars 0.00 / 5 stars	GBX 69 flat	N/A	+21.4%	£48.69M	£29.49M	-3,450.00	82	High Trading Volume
SAR Sareum	0 of 5 stars 0.00 / 5 stars	GBX 34.50 -1.4%	N/A	-68.5%	£37.24M	£47,204.00	-575.00	3,211	News Coverage